Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Breast Cancer Research

Volumn 10, Issue 3, 2008, Pages

  Magkou, Christina ^a   Nakopoulou, Lydia ^a   Zoubouli, Christina ^a   Karali, Kanelina ^b   Theohari, Irene ^a   Bakarakos, Panagiotis ^a   Giannopoulou, Ioanna ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MENOPAUSE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 55749100008     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2103     Document Type: Article

References (37)

1. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005, 24:47-69. 10.1007/s10555-005-5047-1, 15785872.
2. Janinis J, Nakopoulou L, Panagos G, Davaris P. Immunohistochemical expression of EGF-R in malignant surface epithelial ovarian neoplasms (SEON). Eur J Gynaecol Oncol 1994, 15:19-23. 8206065.
3. Nakopoulou L, Zervas A, Constantinides C, Deliveliotis C, Stefanaki K, Dimopoulos C. Epithelial differentiation antigens and epidermal growth factor receptors in transitional cell bladder carcinoma: correlation with prognosis. Urol Int 1995, 54:191-7.
4. Bianco R, Gelardi T, Damiano V, Ciardello F, Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007, 39:1416-1431. 10.1016/j.biocel.2007.05.008, 17596994.
5. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys. 2004, 58:932-940. 14967453.
6. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006, 1766:120-39.
7. Suo Z, Risberg B, Kalsson M, Willman K, Tierens A, Skovlund E, Nesland J. EGFR family expression in breast carcinomas. c-erb-B-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25. 10.1002/path.1003, 11748637.
8. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor ADL. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005, 23:1152-1160. 10.1200/JCO.2005.09.055, 15718311.
9. Gohring U-J, Ahr A, Scharl A, Weisner V, Neuhaus W, Crombach G, Holt JA. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma. J Soc Gynecol Invest 1995, 2:653-659. 9420872, 10.1016/1071-5576(95)00013-5.
10. Lewis S, Locker A, Todd JH, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990, 43:385-389. 502437, 2370306, 10.1136/jcp.43.5.385.
11. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71:67-75. 10.1023/A:1013397232011, 11859875.
12. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13:3-17. 10.1210/er.13.1.3, 1313356.
13. Johnson RS, Arteaga CL. Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?. J Clin Oncol 2003, 21:2227-2229. 10.1200/JCO.2003.04.001, 12748243.
14. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 2003, 9:1579-1589.
15. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003, 13:289-298.
16. Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T, Hilbe W. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol 2006, 59:255-259. 10.1136/jcp.2005.027615, 16505275.
17. Tavassoli FA, Davilee P. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs 2003, Lyon, France: International Agency for research on Cancer Press.
18. Robins P, Pinder S, de Klerk N. Histological grading of breast carcinomas: a study of interobserver agreement. Human Pathol 1995, 26:873-879. 7635449, 10.1016/0046-8177(95)90010-1.
19. American Joint Committee on Cancer Breast. AJCC Cancer staging Manual 2002, 171-180. New York: Springer, Greene FL, 6, American Joint Committee on Cancer.
20. Putti TC, To KF, Hsu HC, Chan ATC, Lai GM, Tse G, Lee YS, Whang-Peng J, Millward M, Lin L, Lin X, Lee CS. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 2002, 41:144-151. 10.1046/j.1365-2559.2002.01436.x, 12147092.
21. Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli C, Keramopoulos A, Nakopoulou L. The prognostic value of the topographic distibution of uPAR expression in invasive breast carcinomas. Cancer Lett 2007, 246:262-267. 10.1016/j.canlet.2006.03.003, 17319000.
22. Mylona E, Alexandrou P, Giannopoulou I, Liapis G, Markaki S, Keramopoulos A, Nakopoulou L. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol 2007, 104:557-563. 10.1016/j.ygyno.2006.09.031, 17150246.
23. Mylona E, Nomikos A, Magkou C, Kamberou M, Panayotides I, Papassideri I, Keramopoulos A, Nakopoulou L. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 2007, 50:338-347. 10.1111/j.1365-2559.2007.02615.x, 17257129.
24. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 2001, 490:142-152. 10.1016/S0014-5793(01)02117-2, 11223029.
25. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004, 10:5670-5676. 10.1158/1078-0432.CCR-04-0110, 15355892.
26. Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol 2005, 12:271-273. 10.1097/01.pap.0000184178.43048.80, 16210923.
27. Nicholson RI, McCelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res 1994, 29:117-125. 7912565, 10.1007/BF00666187.
28. Newby JC, Johnson SR, Smith EL, Dorosett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997, 3:1643-1651. 9815855.
29. Knoop A, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C. Value of epidermal growth factor receptor, HER-2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high risk postmenopausal breast cancer patients. J Clin Oncol 2001, 19:3376-3384.
30. Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001, 55:108-121. 10.1002/jemt.1162, 11596156.
31. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-395. 10.1016/S0898-6568(01)00271-6, 11882383.
32. Duffy MJ, Maguire TM, Hill A, McDermott E. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257. 138784, 11250717, 10.1186/bcr65.
33. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mansel RE. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006, 17:583-590.
34. Andreasen PA, Kjoeller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72:1-22. 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z, 9212216.
35. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimp DL. B-catenin and p-53 analysis of a breast carcinoma tissue micrarray. Cancer 2004, 100:2084-2092. 10.1002/cncr.20232, 15139049.
36. Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Robertson JF, Ellis IO. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?. Clin Cancer Res 2004, 10:2578. 15073139.
37. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 2007, 25:4405-13. 10.1200/JCO.2006.09.8822, 17906204.